Safety and tolerability of agalsidase beta infusions shorter than 90 minutes in patients with Fabry disease: post-hoc analysis of a Japanese post-marketing study

Abstract

Abstract Background: Agalsidase beta, an enzyme replacement therapy for Fabry disease, is dosed biweekly at 1 mg/kg body weight, with increasing infusion rates based on tolerability. The US label specifies ≥90-minute infusions for all patients; the US and EU labels require ≤15 mg/hr infusions in patients <30 kg. The Japanese label allows infusions up to 30 mg/hr, allowing <90-minute dosing for some patients weighing <45 kg. Japanese post-marketing data were analyzed for rate of infusion-associated reactions (IARs), adverse events (AEs), and serious AEs (SAEs) based on infusion rate and patient attributes (weight, antibody status). Results: Data were available for 436 reduced-duration infusions (<90 minutes) and 2,242 standard infusions (≥90 minutes). SAEs were rare (0.6%), and the frequency of all safety events decreased over the treatment course. Little impact of infusion duration on safety outcomes was observed: IARs and AEs were numerically more common when infusion duration was ≥90 minutes compared to <90 minutes (IARs: 2.0% vs 0.9%; AEs: 2.9% vs 1.4%), while the rate of SAEs was similar (0.4% vs 0.5%). IAR, AE, and SAE frequencies decreased significantly with increasing infusion rates, and this trend was consistent in patients <30 kg. Safety events tended to be less frequent in patients <30 kg vs those ≥30 kg (IARs: 1.8% vs 2.1%; AEs: 2.3% vs 3.6%; SAEs: 0.0% vs 0.6%), although the differences were not statistically significant. IARs occurred in <1% of all infusions in the <30 kg group, 84% of which were <90 minutes. More anti-agalsidase beta antibody-positive patients experienced IARs (41.9% vs 30.7%; P=0.0445) and AEs (61.1% vs 49.3%; P=0.0497) vs antibody-negative patients; however, there was no significant difference in the frequency of SAEs. Conclusions: The results of this post-hoc analysis demonstrated no significant impact of infusion duration on safety outcomes, and no significant difference in outcomes between patients of different weights. These findings suggest that infusion times in patients who are tolerating treatment can, with careful monitoring, be gradually decreased.